EVENTS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting – Poster Presentation
Next-Generation Immunostimulatory Antibody-Drug Conjugates (iADCs) Combine Tumor Cell Killing with Immune Activation to Induce Durable Antitumor Immunity
16th Annual World ADC San Diego – Presentations
Showcasing Development of Site-Specific, High-DAR Dual-Payload ADCs Presenter: Daniel Calarese, Ph.D.Developing Next-Generation Immunostimulatory Dual Payload ADCs to Enhance Therapeutic Index & Tackle Patient Resistance Presenter: Gang Yin, Ph.D.Laying Out...
Sutro R&D Day – Presentation
Sutro Biopharma to Host Virtual Research & Development Day on November 12, 2025
SOUTH SAN FRANCISCO, Calif., November 5, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it will host a virtual Research &...
Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference
SOUTH SAN FRANCISCO, Calif., November 3, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced its participation at the 16th Annual World ADC...
21st Annual PEGS Boston Summit – Presentation
The Citizens Life Sciences Conference – Presentation
Sutro Biopharma to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 1, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will participate in two upcoming...
2025 American Association for Cancer Research (AACR) Annual Meeting – Poster Presentations
Title: Preclinical activity and safety of STRO-004, a novel ADC targeting tissue factor for solid tumors Abstract: #1572 Session: PO.ET02.01 - Antibody-Based Cancer Therapeutics 1 Date & Time: Monday, April 28, 2025, 9:00 a.m. - 12:00 p.m. CTPresenter: Alice Yam,...
Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025
- Preclinical findings show STRO-004's promising anti-tumor activity and favorable safety profile - SOUTH SAN FRANCISCO, Calif., April 28, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format...